Can MCI-186 slow ALS? phase 3 trial results revealed
NCT ID NCT01492686
First seen Jan 07, 2026 · Last updated May 05, 2026 · Updated 19 times
Summary
This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. Participants received daily IV infusions of the drug or a placebo for 24 weeks. The goal was to see if MCI-186 could slow the disease's progression, measured by a scale that tracks daily function. The trial was completed and compared changes between the drug and placebo groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Osaka, Japan
Conditions
Explore the condition pages connected to this study.